Is TTF-1 a prognostic marker in non-small cell lung adenokarsinoma?
Thyroid transcription factor-1 (TTF-1) is first found to be a promoter of the thyroglobulin. The primary function of this protein is the regulation of nuclear transcription.TTF-1 has suggested having both oncogenic and anti-oncogenic effects on tumor biology. A total number of 1104 patient’s data with lung cancers are evaluated. When the patients without adenocarcinoma histology, unknown TTF-1 status, and lost follow-up were excluded, the remaining total number of 104 patient’s characteristics, chemotherapy types, treatment responses (as accommodation with Response Evaluation Criteria in Solid Tumors), progression-free survival (PFS) and overall survival (OS) were recorded and analyzed.TTF-1 positivity is significantly correlated with the female gender. The biopsy location among the groups was statistically different between the TTF-1 positive and negative groups. The EGFR mutation rate was significantly higher in the TTF-1 positive group. In the survival analysis, the TTF-1 positive patients have a significantly better OS in all study population. The statistically significant survival advantage was going on in the TTF-1 positive group when the TKI treated patients excluded. The PFS was not significantly different between the two groups. However, when the TKI treated patients excluded in both groups; the TTF-1 positive group had a significantly better PFS. In conclusion, TTF-1 positivity may be used as a positive prognostic marker for lung adenocarcinoma independent from TKI usage because of strongly correlated with a better OS.
___
1. Civitareale D, Lonigro R, Sinclair AJ, et al. A thyroid-specific nuclear protein essential for tissue-specific expression of the thyroglobulin promoter. EMBO J. 1989;8:2537-42.2. Kimura S, Hara Y, Pineau T, et al. The T/ebp null mouse: Thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary. Genes Dev. 1996;10:60-9.
3. Lazzaro D, Price M, Felice D, et al. The transcription factor TTF-1 is expressed at the onset of thyroid and lung morphogenesis and in restricted regions of the fetal brain. Development. 1991;113:1093-104.
4. Minoo P, Hamdan H, Bu D, et al. TTF-1 regulates lung epithelial morphogenesis. Dev Biol.1995;172:694-8.
5. Alam MN, Berhane K, Boggaram V. Lung surfactant protein B promoter function is dependent on the helical phasing, orientation and combinatorial actions of cis-DNA elements. Gene. 2002;282:103-11.
6. Goldstein NS, Thomas M. Mucinous and nonmucinous bronchioloalveolar adenocarcinomas have distinct staining patterns with thyroid transcription factor and cytokeratin 20 antibodies. Am J Clin Pathol. 2001;116:319-25.
7. Ordóñez NG. Thyroid transcription factor-1 is a marker of lung and thyroid carcinomas. Advances in Anatomic Pathology. 2000;7:123-7.
8. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244-85.
9. Kendall J, Liu Q, Bakleh A, et al. Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. Proc Natl Acad Sci. 2007;104:16663-8.
10. Kwei KA, Kim YH, Girard L, et al. Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene. 2008;27:3635-40.
11. Tanaka H, Yanagisawa K, Shinjo K, et al. Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res. 2007;67:6007–11.
12. Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007;450:893-8.
13. Saito R-A, Watabe T, Horiguchi K, et al. Thyroid transcription factor-1 inhibits transforming growth factor-beta-mediated epithelial-to-mesenchymal transition in lung adenocarcinoma cells. Cancer Res. 2009;69:2783-91.
14. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nature Reviews Cancer. 2009;9:265-73
15. Shih JY, Yang PC. The EMT regulator slug and lung carcinogenesis. Carcinogenesis. 2011;32:1299-304.
16. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer ıncidence and mortality worldwide: IARC cancerbase. International Agency for Research on Cancer. 2013;136:E359-86.
17. Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: Male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer. 2005;117:294-9.
18. Hata A, Katakami N, Fujita S, et al. Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar Carcinoma. J Thorac Oncol. 2010;5:1197-200.
19. Kunii R, Jiang S, Hasegawa G, et al. The predominant expression of hepatocyte nuclear factor 4alpha (HNF4alpha) in thyroid transcription factor-1 (TTF-1)-negative pulmonary adenocarcinoma. Histopathology. 2011 Feb;58:467-76.
20. Hwang DH, Sholl LM, Rojas-Rudilla V, et al. KRAS and NKX2-1 mutations in invasive mucinous adenocarcinoma of the lung. J Thorac Oncol. 2016;11:496-503.
21. Chung K-P, Huang Y-T, Chang Y-L, et al. Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase ınhibitor treatment. Chest. 2012;141:420-28.
22. Shanzhi W, Yiping H, Ling H, et al. The relationship between TTF-1 expression and EGFR mutations in lung adenocarcinomas. PLoS One. 2014;9:e95479.
23. Di Loreto C, Di Lauro V, Puglisi F, et al. Immunocytochemical expression of tissue specific transcription factor-1 in lung carcinoma. J Clin Pathol. 1997;50:30–2.
24. Fabbro D, Di Loreto C, Stamerra O, et al. TTF-1 gene expression in human lung tumours. Eur J Cancer. 1996 Mar;32A:512–7.
25. Folpe AL, Gown AM, Lamps LW, et al. Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors. Mod Pathol. 1999;12:5-8.
26. Ordóñez NG. Value of thyroid transcription factor-1 immunostaining in distinguishing small cell lung carcinomas from other small cell carcinomas. Am J Surg Pathol. 2000;24:1217-23.
27. Zhang PJ, Gao HG, Pasha TL, et al. TTF-1 expression in ovarian and uterine epithelial neoplasia and its potential significance, an immunohistochemical assessment with multiple monoclonal antibodies and different secondary detection systems. Int J Gynecol Pathol. 2009;28:10-8.
28. Penman D, Downie I, Roberts F. Positive immunostaining for thyroid transcription factor-1 in primary and metastatic colonic adenocarcinoma: A note of caution. J Clin Pathol. 2006; 59:663-4.
29. Barlési F, Pinot D, LeGoffic A, et al. Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung. Br J Cancer. 2005; 93(4): 450–2.
30. Barletta JA, Perner S, Iafrate AJ, et al. Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. J Cell Mol Med. 2009;13:1977-86.
31. Berghmans T, Paesmans M, Mascaux C, et al. Thyroid transcription factor 1--a new prognostic factor in lung cancer: a meta-analysis. Ann Oncol. 2006;17:1673-6.
32. Perner S, Wagner PL, Soltermann A, et al. TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival. J Pathol. 2009;217:65-72.
33. Schilsky JB, Ni A, Ahn L, et al. Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas. Lung Cancer. 2017;108:205-11.
34. Elsamany SA, Al-Fayea TM, Alzahrani AS, et al. Thyroid transcription factor-1 expression in advanced non- small cell lung cancer: impact on survival outcome. Asian Pac J Cancer Prev. 2015;16:2987-91.
35. Grønberg BH, Lund-Iversen M, Strøm EH, et al. Associations between TS, TTF-1, FR-α, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy. J Thorac Oncol. 2013;8:1255-64.
36. Martins SJ, Takagaki TY, Silva AG, et al. Prognostic relevance of TTF-1 and MMP-9 expression in advanced lung adenocarcinoma. Lung Cancer. 2009;64:105-9.
37. Takezawa K, Okamoto I, Okamoto W, et al. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. Br J Cancer. 2011;104:1594-601.
38. Sun J-M, Han J, Ahn JS, et al. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. J Thorac Oncol. 2011;6:1392-9.
- ISSN: 2147-0634
- Yayın Aralığı: Yılda 4 Sayı
- Başlangıç: 2012
- Yayıncı: Effect Publishing Agency ( EPA )
Sayıdaki Diğer Makaleler
Protective effects of curcumin on liver damage in rats treated with chlorpyrifos during pregnancy
Tarik DEMİR, Ezgi COBAN, Murat ARAZ, Altay ALİYEV, Mesut SEKER, Haci Mehmet TURK
Neslihan ALTUNKAYA, Duygu Demiroz ASLAN
Ahmet Hamdi KEPEKCİ, Kadir DASTAN
Dosay Mine AKBULUT, Ayhan VURMAZ
Ayhan TANYELİ, Ersen ERASLAN, Mustafa Can GULER, Saime Ozbek SEBİN, Demet CELEBİ, Fatma Betul OZGERİS, Erdem TOKTAY
Ahmet SOYUCOK, Kerim ASLAN, Murat DANACI, Ilkay CAMLİDAG
Stroke awareness in people with hypertension
The comparison of DNA extraction techniques in human bone and tooth samples exposed to high heat
Emel Hulya YUKSELOGLU, Kadir DASTAN, Fatma Cavus YONAR, Gülten RAYİMOĞLU, Ömer KARATAŞ, Dilek Salkim ISLEK, Muzaffer Berna DOGAN
Some features of hospitalized elderly and effects of fall behavior on fall risk